| Trial ID: | L2751 |
| Source ID: | NCT01001962
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
|
| Acronym: |
PREHYPD
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension|Type II Diabetes
|
| Interventions: |
DRUG: empagliflozin|DRUG: Metformin
|
| Outcome Measures: |
Primary: New onset of hypertension, 36 months | Secondary: 24h blood pressure levels, 36 months|Total cardiovascular risk, 36 months|Morbidity cardiovascular, 36 months|Arterial stiffness, 36 months|Central aortic blood pressure, 36 months|Mortality cardiovascular, 36 months
|
| Sponsor/Collaborators: |
Sponsor: Aristotle University Of Thessaloniki
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
1054
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2016-01
|
| Completion Date: |
2020-01
|
| Results First Posted: |
|
| Last Update Posted: |
2015-04-07
|
| Locations: |
Hypertension 24h ABPM center Papageorgiou Hospital, Thessaloniki, Greece
|
| URL: |
https://clinicaltrials.gov/show/NCT01001962
|
